Literature DB >> 24280222

Multimeric growth hormone receptor complexes serve as signaling platforms.

Magdalena Sedek1, Lieke M van der Velden, Ger J Strous.   

Abstract

Growth hormone (GH) signaling is required for promoting longitudinal body growth, stem cell activation, differentiation, and survival and for regulation of metabolism. Failure to adequately regulate GH signaling leads to disease: excessive GH signaling has been connected to cancer, and GH insensitivity has been reported in cachexia patients. Since its discovery in 1989, the receptor has served a pivotal role as the prototype cytokine receptor both structurally and functionally. Phosphorylation and ubiquitylation regulate the GH receptor (GHR) at the cell surface: two ubiquitin ligases (SCF(βTrCP2) and CHIP) determine the GH responsiveness of cells by controlling its endocytosis, whereas JAK2 initiates the JAK/STAT pathway. We used blue native electrophoresis to identify phosphorylated and ubiquitylated receptor intermediates. We show that GHRs occur as ∼500-kDa complexes that dimerize into active ∼900-kDa complexes upon GH binding. The dimerized complexes act as platforms for transient interaction with JAK2 and ubiquitin ligases. If GH and receptors are made in the same cell (autocrine mode), only limited numbers of ∼900-kDa complexes are formed. The experiments reveal the dynamic changes in post-translational modifications during GH-induced signaling events and show that relatively simple cytokine receptors like GHRs are able to form higher order protein complexes. Insight in the complex formation of cytokine receptors is crucially important for engineering cytokines that control ligand-induced cell responses and for generating a new class of therapeutic agents for a wide range of diseases.

Entities:  

Keywords:  Blue Native Electrophoresis; Cell Signaling; Cell Surface Receptor; Cytokine Action; Cytokine Receptor; Growth Hormone; Hexamers; JAK Kinase; JAK2; SCFβTrCP2

Mesh:

Substances:

Year:  2013        PMID: 24280222      PMCID: PMC3879580          DOI: 10.1074/jbc.M113.523373

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins.

Authors:  P van Kerkhof; C M Alves dos Santos; M Sachse; J Klumperman; G Bu; G J Strous
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

2.  Endocytosis and degradation of the growth hormone receptor are proteasome-dependent.

Authors:  P van Kerkhof; R Govers; C M Alves dos Santos; G J Strous
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

3.  Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination.

Authors:  H Suzuki; T Chiba; T Suzuki; T Fujita; T Ikenoue; M Omata; K Furuichi; H Shikama; K Tanaka
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

4.  Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor.

Authors:  R Govers; P van Kerkhof; A L Schwartz; G J Strous
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

5.  Ubc13 and COOH terminus of Hsp70-interacting protein (CHIP) are required for growth hormone receptor endocytosis.

Authors:  Johan A Slotman; Ana C da Silva Almeida; Gerco C Hassink; Robert H A van de Ven; Peter van Kerkhof; Hendrik J Kuiken; Ger J Strous
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

6.  The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand.

Authors:  P van Kerkhof; G J Strous
Journal:  Biochem Soc Trans       Date:  2001-08       Impact factor: 5.407

7.  Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains.

Authors:  P van Kerkhof; M Sachse; J Klumperman; G J Strous
Journal:  J Biol Chem       Date:  2000-10-19       Impact factor: 5.157

8.  SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol.

Authors:  Magdalena Sedek; Ger J Strous
Journal:  Biochem J       Date:  2013-07-15       Impact factor: 3.857

9.  Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma.

Authors:  Severine E Brunet-Dunand; Cecile Vouyovitch; Silvia Araneda; Vijay Pandey; Laurent J-P Vidal; Cristin Print; Hichem C Mertani; Peter E Lobie; Jo K Perry
Journal:  Endocrinology       Date:  2008-10-30       Impact factor: 4.736

10.  Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor.

Authors:  Joyce Putters; Ana C da Silva Almeida; Peter van Kerkhof; Agnes G S H van Rossum; Ana Gracanin; Ger J Strous
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

View more
  12 in total

1.  Dynamic analysis of GH receptor conformational changes by split luciferase complementation.

Authors:  Ying Liu; Philip A Berry; Yue Zhang; Jing Jiang; Peter E Lobie; Ramasamy Paulmurugan; John F Langenheim; Wen Y Chen; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2014-09-04

2.  Fos-Zippered GH Receptor Cytosolic Tails Act as Jak2 Substrates and Signal Transducers.

Authors:  Tobias Nespital; Lieke M van der Velden; Anneloes Mensinga; Elisabeth D van der Vaart; Ger J Strous
Journal:  Mol Endocrinol       Date:  2016-02-09

3.  GH/STAT5 signaling during the growth period in livers of mice overexpressing GH.

Authors:  Carolina S Martinez; Verónica G Piazza; María E Díaz; Ravneet K Boparai; Oge Arum; María C Ramírez; Lorena González; Damasia Becú-Villalobos; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  J Mol Endocrinol       Date:  2015-02-17       Impact factor: 5.098

4.  Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.

Authors:  Ying Liu; Jing Jiang; Bradford Lepik; Yue Zhang; Kurt R Zinn; Stuart J Frank
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

5.  GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.

Authors:  Ying Liu; Yue Zhang; Jing Jiang; Peter E Lobie; Ramasamy Paulmurugan; John F Langenheim; Wen Y Chen; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2016-03-22

6.  Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.

Authors:  Reetobrata Basu; Shiyong Wu; John J Kopchick
Journal:  Oncotarget       Date:  2017-03-28

Review 7.  Classical and novel GH receptor signaling pathways.

Authors:  Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2020-08-22       Impact factor: 4.102

8.  Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma.

Authors:  Ramadevi Subramani; Rebecca Lopez-Valdez; Alyssa Salcido; Thiyagarajan Boopalan; Arunkumar Arumugam; Sushmita Nandy; Rajkumar Lakshmanaswamy
Journal:  Exp Mol Med       Date:  2014-10-10       Impact factor: 8.718

Review 9.  A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging?

Authors:  Vibhuti Joshi; Ayeman Amanullah; Arun Upadhyay; Ribhav Mishra; Amit Kumar; Amit Mishra
Journal:  Front Mol Neurosci       Date:  2016-10-04       Impact factor: 5.639

10.  Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival.

Authors:  Jin Dai; Zhe-Xuan Li; Yang Zhang; Jun-Ling Ma; Tong Zhou; Wei-Cheng You; Wen-Qing Li; Kai-Feng Pan
Journal:  Clin Transl Gastroenterol       Date:  2019-01       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.